update - Epipen manufacturer Meridian Medical Technologies completes investigation

Meda recalls EpiPen batch in Denmark after reports of defects

By Gareth Macdonald contact

- Last updated on GMT

istock/Roel Smart
istock/Roel Smart

Related tags: Recall election

Mylan subsidiary Meda has recalled a batch of EpiPens in Denmark after reports some have defective auto-injectors.

The product withdrawal – which was detailed​ on the Danish Medicines Agency (DKMA) – covers 499 Epipens (epinephrine injection, USP) from batch number 5FA665B, which Meda had intended to sell in Denmark.

The DKMA said: “The withdrawal follows from two reports of a defective EpiPen with this batch number. Against this background, there is a low risk that EpiPen does not work in rare cases.

Consequently, there is a low risk that patients who experience a severe hypersensitivity reaction cannot treat themselves with an adrenaline injection​.”

This was confirmed by Meda spokeswoman who told us "Meda initiated the voluntary recall after receiving two reports of failure to activate the device due to a possible defect. The recall is a precautionary measure."

She added that: "The recalled product was manufactured by Meridian Medical Technologies in the US​.

"An investigation has been conducted by our manufacturing partner Meridian Medical Technologies and it has been observed that there may be a very small probability in lot 5FA665 that the auto-injector may not work correctly​."

No shortages

The recall is unlikely to result in shortages according to the DKMA, which said: “There are other product numbers and batches of EpiPen on the market that are not affected by this withdrawal​.”

Other firms that supply the Danish market include Orifarm and 2care4, both of which parallel import the product.

Meda began selling Epipen last year​ after it was acquired by Mylan.

Related news

Show more

Related products

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers